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Insulin-like growth factor binding protein-5 (IG-
FBP-5) is an important modulator of IGF actions. IG-
FBP-5 mRNA is abundant in human fibroblasts and is
regulated by cAMP. To understand the molecular mech-
anism underlying this cell type-specific expression and
regulation, we isolated the 5*-flanking region of the hu-
man IGFBP-5 gene and fused it to a promoter-less re-
porter plasmid encoding luciferase. Transient transfec-
tion of the construct into fibroblasts displayed both
constitutive and cAMP-induced promoter activity in an
orientation-specific manner. Sequence analysis re-
vealed the existence of distal and proximal consensus
AP-2 recognition sites located 5* from the TATA box.
Both sequences bound specifically to human AP-2 in
vitro by gel shift mobility assay. The possible role of
AP-2 was examined by cotransfection of AP-2-deficient
HepG2 cells with the IGFBP-5 promoter construct and a
human AP-2 expression construct. Cotransfection with
AP-2 significantly elevated IGFBP-5 promoter activity.
This trans-activation was IGFBP-5 promoter and AP-2
specific. In AP-2 abundant fibroblasts, expression of AP-
2B, a dominant-negative inhibitor of AP-2, suppressed
IGFBP-5 promoter activity. In HepG2 cells, AP-2B alone
had no significant effect, but the AP-2-induced activa-
tion of promoter activity was inhibited by AP-2B in a
dose-dependent manner. The relative functional impor-
tance of the putative AP-2 binding sites was examined
using a number of deletion mutants and point muta-
tions. When the first two distal CCCCACCC-like putative
AP-2 sites were deleted or mutated, there was no change
in AP-2-induced trans-activation. Deletion or mutation
of the proximal GCCNNNGGC-like sequences, however,
abolished the AP-2-induced activation. These results
suggest that AP-2 regulates the IGFBP-5 gene expres-
sion through the proximal GCCNNNGGC-like se-
quences. This AP-2-mediated trans-activation contrib-
utes at least in part to the constitutively high expression
of IGFBP-5 in fibroblasts and to the cAMP responsive-
ness of this gene.
Insulin-like growth factor I and II (IGF-I and IGF-II)1 are
multifunctional growth factors required for normal develop-
ment and growth in vertebrate animals. IGF-I mediates many
of the growth-promoting effects of growth hormone during post-
natal life (1) and both IGF-I and -II have been shown to be
important for fetal growth in gene targeting experiments (2).
In extracellular fluids the IGFs are bound to one of the
members of a family of soluble, high affinity binding proteins
(3). These IGF binding proteins (IGFBPs) act as carrier pro-
teins in plasma to control the efflux of IGFs from the vascular
space and prolong their half-lives. More importantly, since they
bind to IGFs with higher affinities than the IGF receptors,
IGFBPs provide a means of localizing IGFs on target cells.
Furthermore, they can alter the biological activity of IGFs by
modulating their interaction with IGF receptors (1). Six dis-
tinct IGFBPs, designated as IGFBP-1 to 6, have been isolated
and cloned and each represents an individual gene product.
They share relatively high amino acid sequence similarity but
each has distinct structural and biochemical properties and
each is subject to differential tissue-specific expression, devel-
opmental and hormonal regulation (4). This suggests that each
IGFBP may play a specific role in regulating the biological
actions of IGFs in defined tissues.
IGFBP-5 is the most conserved of the six known IGFBPs.
This 252-amino acid protein is more than 97% identical among
human, rat, and mouse (5). IGFBP-5 has the unique property of
associating with cell surfaces and adhering to extracellular
matrix (1). When associated with the extracellular matrix, it
has been shown to potentiate the effect of IGFs on fibroblast
growth (6). In addition, IGFBP-5 may also be involved in cell
differentiation. The expression of IGFBP-5 is greatly increased
during terminal differentiation of the mouse C2 myoblast cell
line in vitro and overexpression of IGFBP-5 alters the differ-
entiation of these cells (5, 7). IGFBP-5 mRNA is abundant in
several tissues in adult animals, including kidney, brain, gut,
uterus, and cardiac and skeletal muscle but is minimal in liver
(5, 8, 9). In the rat embryo, IGFBP-5 mRNA is detected as early
as embryonic day 10.5 and is mainly distributed at the surface
ectoderm, the notochord, the floor plate, limb buds, precursor
cells for neuronal cells, and specific muscle cells (10). In vitro,
the level of expression of IGFBP-5 varies between cell types
and is regulated by specific factors such as RA and IGF-1 in a
cell type-specific manner (11–14). Previously we reported that
IGFBP-5 mRNA was significantly induced by forskolin in hu-
man fetal skin fibroblasts, suggesting that IGFBP-5 is regu-
lated by intracellular cAMP levels (15). A similar increase was
also reported in rat osteoblast-like cells by parathyroid hor-
mone through a cAMP-mediated mechanism (16). The molecu-
lar mechanisms underlying the tissue-specific expression and
hormonal regulation of the IGFBP-5 gene are undefined.
This study was undertaken to characterize cis-acting se-
quences and their corresponding trans-acting factors that are
responsible for the constitutively high expression in connective
tissues and for the cAMP responsiveness of the human IG-
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FBP-5 gene. We have cloned the 59-flanking region of the hu-
man IGFBP-5 gene from a genomic DNA library and confirmed
the structure published recently by Allander et al. (17). We
report here that the developmentally regulated transcription
factor AP-2 stimulates transcription of the IGFBP-5 gene and
that this trans-activation is at least in part responsible for the
constitutively high expression in fibroblasts and for the cAMP
responsiveness of this gene. We found that AP-2 regulates
IGFBP-5 gene expression through a 59-GCCNNNGGC-39-like
sequence but not 59-CCCCACCC-39 sequences in vivo, although
both sequences have been proposed as consensus AP-2 binding
sites (18, 19) and both were capable of binding to AP-2 in vitro.
MATERIALS AND METHODS
Cloning of the IGFBP-5 Gene—A human genomic DNA library con-
structed in Lambda Fix II vector (Stratagene, La Jolla, CA) was
screened using a 627-base pair (bp) human IGFBP-5 cDNA, which was
labeled with [32P]dCTP (Amersham) by a random priming kit (Boeh-
ringer Mannheim). DNA from plaque-purified positive clones was di-
gested with NotI, and the resulting fragments were selected by size and
hybridized to a 261-bp cDNA fragment spanning the first exon of
IGFBP-5. The selected inserts were subcloned into Bluescript vector
(Stratagene). The nucleotide sequence of the largest fragment (7 kb)
was partially sequenced following the dideoxy nucleotide method using
double-stranded DNA sequencing with Sequenase Version 2 (U. S.
Biochemical Corp.). This fragment contains 1.3 kb of the 59-flanking
region of the gene.
Plasmid Construction—IGFBP-5 promoter/luciferase constructs
(pBP5P/Luc) were made by fusing human IGFBP-5 DNA fragment to a
promoter-less luciferase vector (pGL2-Basic, Promega, Madison, WI). A
DNA fragment consisting of 1278 nucleotides 59 to the ATG translation
start codon was generated by polymerase chain reactions. The ATG
codon was mutagenized into GTG to avoid potential frameshifts. The
DNA fragment was cloned into pGL2-Basic vector in a sense or anti-
sense orientation. The constructs were verified by DNA sequencing.
The human AP-2 expression plasmid SPRSV-AP-2 and the control
vector SPRSV-LTR were provided by Dr. Trevor Williams (19). The
human AP-2B expression plasmid pSG5-AP-2B was provided by Dr.
Michael A. Tainsky (20).
Mutagenesis—Two sets of mutants were constructed to analyze the
function of the multiple putative AP-2 binding sites. Sequence position
numbering in the human IGFBP-5 gene is relative to the cap site, which
is 772 bp 59 to the first nucleotide of ATG (17). In the first set, mutants
with various lengths of the 59-flanking region was generated by polym-
erase chain reaction or by site-directed mutagenesis. Construct pBP5P1
is identical to pBP5P except the deletion of the 59 122-bp sequence. This
construct contains all the putative AP-2 sites. Further deletion of the
region from 2381 to 2128 where the two CCCCACCC sites are located
generated the construct pBP5P2. Oligonucleotide 59-TACAAACTG-
GCTGCTATTTAAAAGCGC-39 was used to further delete 15 nucleo-
tides from bp 252 to 237 and thus deleted all three putative AP-2
binding sites, generating the construct pBP5P3. All of the sequence 59
of the TATA box was deleted in the construct pBP5P4. These DNA
fragments were subcloned into pGL2-Basic vector and all plasmids
were sequenced to verify proper orientation.
In the second set of mutants, points mutants of pBP5P/Luc were
generated by site-directed mutagenesis as described previously (6).
Plasmid DNA was transfected into Escherichia coli strain CJ236. A
60-ml culture was inoculated and cultured with a fresh colony of CJ236
and was then infected with helper phage R408. After 5 h the bacteria
were pelleted. Phagemid particles were precipitated in 16% polyethyl-
ene glycol and ammonium acetate, and single strand phagemid DNA
was isolated by binding to glassmilk following the manufacturer’s pro-
tocol (Bio 101, La Jolla, CA). The following complementary oligonucleo-
tides containing mutagenic mismatches were used. Oligonucleotide 59-
TCACACGGGGTGGGCTTTGGAGAGGCCTTCTA-39 mutated the first
distal putative AP-2 site (CCCCACCC, located at bp 2147 to 2140) to
CCAAAGCC, generating mutant MU1. Oligonucleotide 59-AAACTCA-
CAGGTGTAGGCTATGGAGAGGCCTTC-39 mutated the two overlap-
ping distal putative AP-2 sites (CCCCACCCCCACCC, located at bp
2147 to 2134) to CCAAAGCCTCACAC, generating mutant MU2. Oli-
gonucleotide 59- TTAAATAGCCGGACAATGTCTGCCAGCCAG-39 mu-
tated the proximal putative AP-2 site (GCCAGGGGC, located at bp 247
to 239) to TACAGTGTC, generating mutant MU3. These oligonucleo-
tides were phosphorylated with T4 polynucleotide kinase (Promega) for
1 h at 37 °C. An aliquot of the synthesis mixture was used to transform
E. coli strain DH5 aF9 and the positive colonies were selected by
ampicillin resistance. DNA from the resulting colonies was amplified
and DNA sequencing was used to determine the clones containing the
correct sequences.
Cell Culture and DNA Transfection—Cell cultures were grown in
6-well Falcon tissue culture plates. Human fetal dermal fibroblasts
(GM10, Human Mutant Genetic Cell Repository, Camden, NJ), normal
and SV40 T-antigen transformed human fetal lung fibroblasts (IMR-90,
MRC-5, AG 2804, and AG 10076, NIA Aging Cell Culture Depository,
Camden, NJ), and human glioblastoma tumor cells (T98G, American
Type Culture Collection, Rockville, MD) were plated at 3–8 3 105
cells/well and maintained in 2 ml of Eagle’s minimal essential medium
supplemented with serine (21 mg/ml), pyruvate (110 mg/ml), asparagine
(30 mg/ml), penicillin (100 units/ml), streptomycin (100 mg/ml), and 10%
fetal calf serum. Human hepatoma and rhabdomyosarcoma cells
(HepG2 and A673, American Type Culture Collection) were plated at
4–5 3 105 cells/well and were maintained in 2 ml of Dulbecco’s minimal
essential medium with low glucose (1 g/liter) supplemented with 4 mM
glutamine, antibiotics, and 10% calf serum or fetal calf serum. After
culture overnight, cells were exposed to calcium phosphate transfection
buffer with 2 mg of luciferase test plasmid DNA for approximately 6–18
h followed by a 3-min glycerol shock. After transfection the cells were
washed twice and maintained in growth medium. The transfected cells
were harvested 2–3 days later unless otherwise specified. 0.5 mg of
pSV-b-galactosidase control vector DNAwas cotransfected to control for
transfection efficiency.
Luciferase Activity Assay—The amount of cellular extract used in the
luciferase assay was normalized relative to b-galactosidase activity.
Luciferase activities were determined using the Luciferase Assay Sys-
tem (Promega). b-Galactosidase activity was assayed by monitoring the
conversion of o-nitrophenyl-b-D-galactopyranoside to galactose and o-
nitrophenyl at A420 nm. Each experiment was repeated 3–4 times with
duplicate samples.
Gel Mobility Shift Assay—The assays were conducted with the fol-
lowing double-stranded oligonucleotides in which the nucleotides that
differ from the wild type sequence are underlined: A1WT (257) 59-
CTGGCTGGCAGCCAGGGGCCGGCTATT-39 (230); A2WT (2152) 59-
CCTCTCCCCACCCCCACCCCGTGTGA-39 (2127); A1MU (257) 59-
CTGGCTGGCATACAGTGTCCGGCTATT-39 (230); and A2MU (2152)
59-CCTCTCCAAAGCCTCACACCGTGTGA-39 (2127). The consensus
AP-2 oligonucleotide 59-GATCGAACTGACCGCCCGCGGCCC-39 was
purchased from Promega. Complementary single-stranded oligonucleo-
tides were hybridized at room temperature in 100 mM NaCl after
heating for 5 min at 95 °C. Oligonucleotides were end-labeled using T4
polynucleotide kinase (Promega) and [32P]ATP (3,000 Ci/mmol, Amer-
sham). The labeled probes were purified by chromatography (NAP
column, Pharmacia Biotech Inc.). The radiolabeled probes (10,000 cpm)
were incubated with or without competing oligonucleotides and bacte-
rially expressed human AP-2 (Promega) in pH 7.5 buffer containing 4%
glycerol, 1 mMMgCl2, 0.5 mM EDTA, 50 mMNaCl, 0.5 mM dithiothreitol,
10 mM Tris-HCl, and 50 mg/ml poly(dI-dC)-poly(dI-dC) in a final volume
of 20 ml. After 20 min incubation at 4 °C, the DNA-protein complexes
were separated by electrophoresis on a 4% polyacrylamide gel in 0.5 3
TBE buffer and visualized by autoradiography. For supershift assay
experiments, samples were preincubated with 1 ml of antiserum against
human AP-2 (Santa Cruz Biotechnology, Santa Cruz, CA) or 1 ml of
anti-IGFBP-5 antibody for 1 h at room temperature before the addition
of 32P-labeled DNA.
RNA Isolation and Northern Blot Analysis—RNA was isolated from
cell cultures by the TriReagent following the manufacturer’s instruc-
tions (Molecular Research Center, Inc., Cincinnati, OH) and was quan-
tified by spectrophotometry. RNA samples were size-fractionated on a
1.2% agarose formaldehyde gel, blotted, and fixed onto nylon membrane
(Biotrans, ICN Biochemical, Inc.), and hybridized with the [32P]dCTP-
labeled human 627-bp IGFBP-5 cDNA. A cDNA probe for glyceralde-
hyde-3-phosphate dehydrogenase (Ambion, Austin, TX) was used to
assess relative amounts of RNA in the Northern blots.
RESULTS
Cell-specific Expression and cAMP Regulation of the Human
IGFBP-5 Gene—The levels of IGFBP-5 mRNA in several cul-
tured human cell lines were compared by Northern blot anal-
ysis (Fig. 1A). IGFBP-5 mRNA was most abundant in fibroblas-
tic cell lines such as IMR-90, GM-10, MRC-5, and the
glioblastoma cell line T98G (lanes 1, 2, 5, and 3, respectively).
It was not appreciably detected in HepG2 cells and A673 cells
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(lanes 6 and 4). More sensitive reverse-transcriptase polymer-
ase chain reaction, however, revealed the presence of minimal
levels of mRNA in A673 and HepG2 cells (data not shown).
When GM-10 fibroblasts were treated with forskolin, the
IGFBP-5 mRNA abundance increased significantly (2.1-fold,
Fig. 1B), as reported previously (15). These results suggest that
IGFBP-5 is expressed in a cell type-specific manner and that
forskolin induces IGFBP-5 mRNA expression in human
fibroblasts.
Functional Characterization of the IGFBP-5 Gene Regulatory
Region—To investigate the molecular mechanism underlying
this cell type-specific expression and cAMP induction, the 59-
flanking region of the human IGFBP-5 gene was isolated. The
59-flanking region was fused to a luciferase reporter vector and
used to transfect GM-10, HepG2, and A673 cells. In all three
cell lines, the IGFBP-5 regulatory/promoter construct had sig-
nificantly greater activity in directing the reporter gene expres-
sion when inserted in the sense orientation compared with the
antisense orientation (Fig. 2). The basal promoter activity was
higher in transfected GM-10 cells than in A673 and HepG2
cells. Elevation of intracellular cAMP levels by forskolin treat-
ment significantly increased the promoter activity in GM-10
cells (Fig. 2C), but this effect was not seen in HepG2 and A673
cells (Fig. 2, A and B). These results indicate that this promot-
er/regulatory region contains elements essential for cell-spe-
cific expression and cAMP responsiveness.
AP-2 Binds to the Putative AP-2 Elements in the IGFBP-5
Regulatory Region—Since cAMP induces IGFBP-5 expression,
we searched the DNA sequence of the regulatory region for
consensus cAMP responsive cis elements. Several putative
AP-2 binding sites but no consensus sequence for cAMP respon-
sive element or AP-1 binding site was found in this region. The
DNA sequence 59-CCCCACCCCCACCC-39 at position 2147 to
2134 contains two overlapping AP-2 elements 59-
CCCCACCC-39 found in the porcine plasminogen activator
gene and the rat tyrosine aminotransferase gene (18). Another
DNA sequence 59-GCCAGGGGC-39 adjacent to the TATA box
at position 247 to 239 contains sequence identical to the
consensus AP-2 element 59-GCCNNNGGC-39 described by Wil-
liams and Tjian (19). In this proximal region, there are two
other sequences homologous to the consensus sequence, 59-
GGCTGGCAG-39 at position 255 to 247 and 59-GGGGC-
CGGC-39 at position 243 to 235. To examine whether AP-2
could bind to these putative sites, gel shift mobility assays were
performed using 32P-labeled oligonucleotides derived from bp
257 to 230 (probe A1) and bp 2152 to 2126 (probe A2).
Bacterially expressed human AP-2 formed a protein-DNA com-
plex with probe A1 (Fig. 3A, lane 2). The AP-2zDNA complex
with probe A1 was competed effectively by 50-fold excess of
unlabeled A1WT oligonucleotide as well as 50-fold excess of
AP-2 consensus oligonucleotide (Fig. 3A, lanes 3 and 4), but
was not inhibited by 100-fold excess of unlabeled A1MU oligo-
nucleotide in which the putative AP-2 sites were mutated (Fig.
3A, lane 5). Similarly, probe A2 also formed specific protein-
DNA complex with AP-2 (Fig. 3B). This complex was inhibited
by unlabeled A2WT oligonucleotide and AP-2 consensus oligo-
nucleotide but not A2MU oligonucleotide. To determine that
FIG. 1. Northern blot analyses of IGFBP-5 mRNA levels. Total
cellular RNA was prepared as described under “Materials and Meth-
ods” from different cell lines. Ten-mg RNA aliquots were electrophore-
sed and transferred to a nylon membrane and then hybridized with a
32P-labeled human IGFBP-5 cDNA probe. The amounts of RNA in each
lane were verified with a glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) cDNA probe. The arrows denote the 6-kb IGFBP-5 message
and 1.4-kb glyceraldehyde-3-phosphate dehydrogenase message. A, ex-
pression of IGFBP-5 mRNA in several human cell lines; B, effects of
forskolin on IGFBP-5 mRNA expression in GM-10 fibroblasts. Conflu-
ent fibroblast monolayers were incubated in Eagle’s minimal essential
medium (lane 1) or Eagle’s minimal essential medium plus forskolin (10
mM, lane 2) for 18 h.
FIG. 2. Effect of forskolin on human IGFBP-5 promoter activ-
ity in HepG2 (A), A673 (B), and GM-10 (C) cells. A 1278-bp DNA
fragment of the human IGFBP-5 gene 59-flanking region was fused to a
luciferase reporter gene (pGL2-Basic) in a sense or antisense orienta-
tion to generate pBP5P/Luc (sense) and pBP5P/Luc (antisense), respec-
tively. These constructs and the promoter-less vector (pGL2-Basic) were
transiently transfected into cells. After growing in complete medium for
48 h, cells were incubated in serum-free medium with or without
forskolin (10 mM) for another 18 h. The cellular extracts were prepared
and the luciferase activity was measured as described under “Materials
and Methods.” The relative luciferase activities represent the relative
fold value versus the promoter-less pGL2-Basic plasmid. pSV-b-galac-
tosidase was used as an internal control. For all transfection experi-
ments the results reported were obtained from at least three independ-
ent experiments each carried out in duplicate.
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AP-2 is actually the protein binding to these sites, supershift
experiments were performed using an antiserum against AP-2.
As shown in Fig. 3, C and D, the AP-2zA1 and AP-2zA2 complex
was supershifted by addition of an anti-AP-2 antibody (lane 2).
In contrast, the complexes were not affected by addition of
anti-IGFBP-5 antibody (lanes 3, Fig. 3, C and D, respectively).
The results indicate that AP-2 can bind specifically to these two
locations of the IGFBP-5 gene in vitro.
AP-2 Regulates IGFBP-5 Expression in Vivo—To examine
whether AP-2 is functionally involved in regulating IGFBP-5
expression, we performed a series of cotransfection studies
using the IGFBP-5 promoter construct. If the promoter activity
of the IGFBP-5 gene is regulated by AP-2, then expression of
exogenous AP-2 in cells that lack endogenous AP-2 should
increase IGFBP-5 promoter activity. Conversely, interference
of the trans-activating activity of AP-2 in AP-2 abundant fibro-
blasts should reduce the promoter activity. Fig. 4 shows the
results obtained when the human AP-2 expression construct
SPRSV-AP-2 (19) was cotransfected with the pBP5P/Luc con-
struct in the AP-2 deficient HepG2 cells. pBP5P/Luc plasmid
had a low basal promoter activity that was induced up to 5-fold
by the cotransfection of AP-2 (Fig. 4A). In contrast, AP-2 had no
effect on the luciferase activity in cells transfected with vector
pGL2-Basic. The fibroblasts, which have abundant endogenous
AP-2 (28), had a significant level of promoter activity (Fig. 4B).
Cotransfection of the SPRSV-AP-2 construct increased the pro-
moter activity but the magnitude was smaller. These results
suggest that AP-2 is capable of activating IGFBP-5 gene ex-
pression in vivo when expressed in human cells.
AP-2 binds DNA as a homodimer with the binding and
dimerization domain located at the C-terminal region of the
protein (19). AP-2B, an alternatively spliced product from the
AP-2 gene, has the activation domain of AP-2 but lacks the
dimerization and DNA binding domain and can specifically
interfere with endogenous AP-2 activity in a dominant-nega-
tive manner (20). We therefore cotransfected construct pBP5P/
Luc with a AP-2B expression construct (pSG5-AP-2B) (20) in
GM-10 fibroblasts. Expression of AP-2B significantly sup-
pressed the basal IGFBP-5 promoter activity in these cells (Fig.
5A). Similar inhibition of IGFBP-5 promoter activity by AP-2B
expression was also obtained with T98G cells (data not shown).
In HepG2 cells, expression of AP-2B had no significant effect on
the basal promoter activity, but it inhibited the AP-2 induced
activation in a dose-dependent manner (Fig. 5B). Since it is
known that SV40 T-antigen inhibits the trans-activation activ-
ity of AP-2 (21), we tested whether SV40 T-antigen-induced
cellular transformation could suppress the constitutively high
expression of endogenous IGFBP-5 mRNA in fibroblasts. As
shown in Fig. 6, two untransformed human fetal lung fibro-
blast cell lines, MRC-5 and IMR-90, both had high levels of
IGFBP-5 mRNA (lanes 1, 2, 5, and 6) similar to GM-10 fibro-
blasts (lane 9). When these cells were transformed by SV40
T-antigen, the IGFBP-5 mRNA expression was almost com-
pletely abolished (lanes 3, 4, 7, and 8). This inhibition by SV40
T-antigen-induced transformation was specific for IGFBP-5,
FIG. 4. Effects of AP-2 on human IGFBP-5 promoter activity in
HepG2 (A) and GM-10 (B) cells. Human hepatoma cells (HepG2) or
fibroblasts (GM-10) were transiently transfected with either pGL2-
Basic or pBP5P/Luc and cotransfected with either a human AP-2 ex-
pression plasmid pSV-AP-2 (AP-2), the pSV vector without AP-2 se-
quence (vector) or pBluescript DNA control (control). Cellular extract
preparation and the luciferase assays were performed as described for
Fig. 2.
FIG. 3. Binding of human AP-2 to the putative AP-2 binding
sites of the human IGFBP-5 promoter. Gel-shift analysis of bacte-
rially expressed human AP-2 was performed with (A) 32P-labeled A1 or
(B) 32P-labeled A2 double-stranded oligonucleotides as probes. The
probes were incubated with (lane 1) or without AP-2 (lanes 2–5). Com-
petitive binding was shown by inclusion of 50-fold excess of unlabeled
wild type oligonucleotide (lane 3, A1WT or A2WT), mutated oligonu-
cleotide (lane 5, A1MU or A2MU), or consensus AP-2 oligonucleotide
(lane 4, cAP-2). Supershift assays for AP-2zA1 (C) or AP-2zA2 complexes
(D) were performed without (lane 1) or with 1 ml of anti-AP-2 antibody
(lane 2) or 1 ml of anti-IGFBP-5 antibody (lane 3).
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since no significant difference was seen in glyceraldehyde-3-
phosphate dehydrogenase expression. These results indicate
that AP-2 regulates transcription of the human IGFBP-5 gene
and contributes at least in part to its constitutively high ex-
pression in human fibroblasts.
The trans-Activation of IGFBP-5 Gene by AP-2 Is Bipha-
sic—In the cotransfection studies with GM-10 cells, we noticed
that transfection of high amounts of AP-2 DNA often failed to
stimulate the promoter activity and was even inhibitory. High-
level expression of AP-2 has been shown to cause transcrip-
tional “self-interference” and result in inhibition of the AP-2
mediated trans-activation in an “artificial” reporter construct
3XAP2REhMt-tK chloramphenicol acetyltransferase (a con-
struct made by fusing three AP-2 responsive elements of hu-
man MtIIA gene to the herpes simplex virus thymidine kinase
promoter in the vector pBLCAT2 (22). We therefore conducted
studies to examine whether high-level expression of AP-2 could
result in reduced trans-activation ability of AP-2 using the
IGFBP-5 promoter. Transfection of various amounts of SPRSV-
AP-2 DNA in AP-2-deficient HepG2 and A673 cells signifi-
cantly elevated the promoter activity of the IGFBP-5 gene dose
dependently (Fig. 7, A and B). This trans-activation was most
appreciable at a dose of 0.5 mg of DNA/well. In AP-2 abundant
GM-10 fibroblasts, however, AP-2-induced trans-activation
was only obtained at low doses (Fig. 7C). At high doses, the
trans-activation ability of AP-2 was diminished. These results
are unlikely to be attributable to differences in transfection
efficiency because the luciferase activity was normalized by
cotransfection of a b-galactosidase control vector. These results
suggest that the trans-activation of human IGFBP-5 gene tran-
scription by AP-2 is biphasic.
AP-2 Regulates IGFBP-5 Gene Expression through a Proxi-
mal GCCNNNGGC Site—Since multiple putative AP-2 binding
sites (CCCCACCC or GCCNNNGGC-like sequences) are pres-
ent on the promoter/regulatory region of the human IGFBP-5
gene and they were all capable of binding to recombinant
human AP-2 in vitro, we conducted studies to investigate the
relative functional importance of these sites in vivo using
HepG2 cells. A number of deletion mutants, in which these
AP-2 binding sites had been deleted separately, were generated
and transfected with or without SPRSV-AP-2 vector in HepG2
cells. Deletion of the first 59 122 bp slightly increased the basal
promoter activity but had little effect on AP-2-induced activa-
tion (pBP5P1/Luc, Fig. 8). Further deletion of the region from
2381 to 2128 where the two CCCCACCC sites are located
significantly reduced the basal promoter activity (pBP5P2/
Luc). AP-2 expression, however, still increased the promoter
activity up to 4.5-fold. When the proximal region (252 to 237)
was deleted, both the basal activity and AP-2-induced activa-
tion was abolished (pBP5P3/Luc and pBP5P4/Luc), suggesting
that this proximal region is necessary for AP-2-induced activa-
tion. The functional importance of these sites was further ex-
amined using site-directed mutagenesis. When the first distant
putative AP-2 site CCCCACCC (located at bp 2147 to 2138)
was mutated to CCAAAGCC, there was no change in AP-2-
induced activation (MU1, Fig. 9). Mutation of the two distant
putative AP-2 sites CCCCACCCCCACCC (located at bp 2147
to 2134) to CCAAAGCCTCACAC appeared to slightly increase
the AP-2 induced activation (MU2, Fig. 9), but these changes
were not significant. When the proximal putative AP-2 site
FIG. 5. A, inhibition of AP-2 activity by AP-2B on IGFBP-5 promoter
activities in GM-10 fibroblasts. Human fibroblasts (GM-10) were tran-
siently transfected with the pBP5P/Luc construct (2 mg) and an AP-2B
expression plasmid. B, effect of AP-2B on AP-2-induced trans-activation
in HepG2 cells. Human hepatoma cells (HepG2) were transiently trans-
fected with pBP5P/Luc and cotransfected with a human AP-2 expres-
sion plasmid pSV-AP-2 (1AP-2) or pBluescript plasmid DNA (2AP-2).
The cells were cotransfected with various amounts of AP-2B. The mi-
crograms of transfected AP-2 B expression plasmid DNA are shown at
the bottom. The differences in AP-2B DNA amount were compensated
for by using pBluescript DNA.
FIG. 6. Northern blot analyses of IGFBP-5 mRNA levels in
normal (UT) and SV40 T-transformed (T) human fibroblasts.
Ten mg RNA aliquots were electrophoresed and transferred to a nylon
membrane and then hybridized with a 32P-labeled IGFBP-5 cDNA
probe and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
probe. The arrows denote the 6-kb IGFBP-5 message and 1.4-kb glyc-
eraldehyde-3-phosphate dehydrogenase message. The RNA samples
loaded in lanes 1 and 2, 5 and 6 are from normal human fetal lung
fibroblast lines MRC-5 and IMR-90, respectively. Lanes 3 and 4, 7 and
8 are RNA samples isolated from their corresponding transformed cell
lines, AG 2804 and AG10076. RNA samples isolated from GM-10 or
HepG2 cells were used as positive and negative controls.
Activation of the Human IGFBP-5 Gene by AP-224848
GCCAGGGGC (located at bp 247 to 239) was mutated to
GACAGTGTC (MU3, Fig. 9), the AP-2-induced activation was
diminished. These results suggest that the proximal GCC-
NNNGGC sequence is the primary site for AP-2 to bind and
trans-activate the human IGFBP-5 gene in vivo.
DISCUSSION
The results from this study have, for the first time, examined
the role of specific cis-acting sequences and a transcription
factor in the regulation of IGFBP-5 gene expression. We have
identified the promoter/regulatory region of this gene that
showed constitutive promoter activity and cAMP responsive-
ness when transfected in human fibroblasts. We were able to
demonstrate that transcription factor AP-2 regulates IGFBP-5
gene expression through a proximal 59-GCCNNNGGC-39-like
sequence of this promoter region. This AP-2-induced trans-
activation contributes at least in part to the constitutively high
expression in fibroblasts and to the cAMP responsiveness of
this gene.
The IGFBP-5 gene has been recently cloned and character-
ized from rat, mouse, and human (23, 9, 17). A DNA fragment
containing the 59-flanking region of the human gene has been
shown to be able to direct expression of a reporter gene in
human breast cancer cells (17). A more in-depth analysis using
the mouse promoter in human hepatoma HepG2 cells suggests
that the IGFBP-5 promoter has a simple structure, requiring
the TATA box and no more than 125 nucleotides of additional
59 DNA to generate primary promoter activity (24). The cis-
acting sequences and their corresponding trans-acting factors
responsible for the developmental- and cell type-specific regu-
lation of IGFBP-5 expression have not been reported.
Several lines of evidence point to a role for AP-2 in regulating
human IGFBP-5 gene transcription. Elevation of intracellular
cAMP levels increases IGFBP-5 mRNA levels in human skin
fibroblasts (Ref. 15 and this study). Since the IGFBP-5 pro-
FIG. 8. Mapping of the functional AP-2 binding sites in the
human IGFBP-5 promoter. The schematic diagram shows the
pBP5P/Luc construct and a series of 59 and internal deletion mutants
fused to pGL2-Basic reporter gene. The putative AP-2 binding sites are
indicated with open circles (CCCCACCC) or solid circles (GCC-
NNNGGC), respectively. The TATA box is indicated as an open square.
These constructs were cotransfected into HepG2 cells with a human
AP-2 expression plasmid (pSV-AP-2) or a control plasmid (pSV). The
luciferase activities induced by AP-2 represent averages of three inde-
pendent experiments of the relative fold increase as compared to the
control lacking AP-2.
FIG. 7. Effect of varying amount of pSV-AP-2 plasmid DNA on
human IGFBP-5 promoter activity in HepG2 (A), A673 (B), and
GM-10 (C) cells. Cells were transiently transfected with pBP5P/Luc (2
mg) and cotransfected with pSV-AP-2 (AP-2) or pBluescript DNA control
(control). The cellular extracts preparation and the luciferase assay
were performed as described in the legend to Fig. 2. The differences in
AP-2 DNA amount were compensated for by using pBluescript DNA.
FIG. 9. A, schematic diagram showing the pBP5P/Luc construct and a
series of point mutant constructs. The putative AP-2 binding sites are
indicated with open circles (CCCCACCC) or solid circles (GCC-
NNNGGC), respectively. The TATA box is indicated as an open square.
The mutated site is indicated as a cross. B, effects of point mutations in
the putative AP-2 binding sites of human IGFBP-5 promoter. The wild
type and mutant constructs were cotransfected into HepG2 cells with a
human AP-2 expression plasmid (pSV-AP-2) or a control plasmid (pSV).
The luciferase activities stimulated by AP-2 represent averages of the
relative fold increases compared to the control lacking AP-2 in four
independent experiments.
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moter activity was induced to a similar extent by forskolin
treatment (Fig. 2C), this cAMP-induced increase in mRNA is a
transcriptionaly regulated event. Sequence analysis had indi-
cated the presence of several consensus AP-2 binding sites in
the promoter region of the human IGFBP-5 gene. AP-2, origi-
nally purified from HeLa cells, is a 52-kDa nuclear protein that
functions as dimer (21). AP-2 exerts its function in mediating
regulation of gene expression in response to a number of di-
verse signal transduction pathways. Elevation of AP-2 trans-
activity can be elicited by RA (25). In addition to RA, AP-2
mediates transcriptional activation in response to two other
signal pathways, the cAMP-dependent protein kinase A path-
way and the phorbol ester/diacylglycerol-inducible protein ki-
nase C pathway (26, 27). This induction of AP-2 activity is
mediated by a mechanism independent of increased AP-2
mRNA and independent of protein synthesis. A similar effect
by forskolin was observed with IGFBP-5 expression in this
study and IGFBP-5 expression has been reported to be regu-
lated by RA (11, 12, 14). The spatial and temporal expression
pattern of IGFBP-5 is similar to that of AP-2, the latter is
known to be expressed primarily in neural crest cells and their
major derivatives (28). IGFBP-5 mRNA expression like AP-2 is
restricted to a subset of ectodermal and mesodermal tissues
during rodent embryogenesis (10). Neither AP-2 nor IGFBP-5
is significantly expressed in endodermally derived tissues such
as liver. This overlapping expression is also reflected in vitro.
As shown in this study, IGFBP-5 mRNA is abundant in fibro-
blasts and glioblastoma cells, which are known to have high
levels of endogenous AP-2 (28). In the AP-2 deficient HepG2
cells, IGFBP-5 mRNA levels are very low. This similarity in
regulation and pattern of expression is suggestive of a role for
AP-2 in regulating IGFBP-5 expression.
The potential role of AP-2 in regulating IGFBP-5 expression
was addressed by DNA binding studies and transfection stud-
ies. Gel shift mobility assay data suggest that the regions from
2152 to 2127 and from 257 to 230 in the IGFBP-5 promoter
were capable of binding to human AP-2 and mutation of these
regions reduced binding, suggesting that AP-2 may be involved
in binding to these regions and regulating this gene. Evidence
supporting this conclusion is that cotransfection of HepG2 cells
or fibroblasts with a human AP-2 expression plasmid increased
IGFBP-5 transcription level. Northern analysis showed that
the levels of IGFBP-5 mRNA were extremely suppressed in the
SV40 T-transformed human fibroblasts (Fig. 6), suggesting
SV40 T-induced cellular transformation inhibits the expression
of IGFBP-5. This could occur through the inhibition of AP-2,
since SV40 large T-antigen has been shown to inhibit the
trans-activating activity of AP-2 by directly binding to AP-2
and thereby preventing the formation of an AP-2zDNA complex
(21). Furthermore, specific interference of the trans-activation
activity of AP-2 in human fibroblasts by expression of AP-2B, a
dominant-negative inhibitor of AP-2, resulted in reduced IG-
FBP-5 promoter activity. These results suggest that AP-2 is
involved in regulating human IGFBP-5 gene expression. The
extent to which AP-2 might be central in controlling IGFBP-5
expression is still not clear. Our transient transfection studies
with HepG2 cells, however, have shown that expression of
exogenous AP-2 can impart to hepatoma cells the ability to
express IGFBP-5 promoter driven transgenes, and AP-2B
counteracts this activation. These data strongly argue that
AP-2 plays an important role in regulating human IGFBP-5
gene expression.
DNase I footprinting experiments have shown that AP-2
binds to GC-rich sequences that are present in a variety of
cellular and viral promoters and sequences of individual AP-2
binding sites can vary substantially (21, 26). Based on the
sequence comparison of AP-2 binding sites identified by DNase
I footprinting in a number of cellular and viral promoters,
sequences such as 59-CCCCA(G/C)(G/C)C-39 have been pro-
posed as consensus sites (18). DNase I footprinting, however,
does not generate information regarding the contribution of
individual nucleotides within the binding sites. Using methyl-
ation interference assays and missing contact probing assays,
Williams and Tjian (19) identified a palindromic sequence,
59GCCNNNGGC-39, as the core recognition sequence for AP-2
binding. In the promoter region of the human IGFBP-5 gene,
both consensus sequences for AP-2 binding are present. The
DNA sequence 59-CCCCACCCCCACCC-39 at position 2147 to
2134 contains two overlapping AP-2 elements 59-
CCCCACCC-39 found in the porcine plasminogen activator
gene and the rat tyrosine aminotransferase gene (18). The DNA
sequence at position 255 to 235 contains sequences identical
or close to the consensus AP-2 element 59-GCCNNNGGC-39
(19). Although both sequences were capable of binding to AP-2
in vitro, the promoter activity data of serially 59-deleted
IGFBP-5 promoter constructs showed that the region between
positions 252 and 237 contains determinants important for
the AP-2-induced activation of transcription. Using a number
of point mutants, we were able to assign the AP-2-induced
activation of the promoter to the proximal sequences which
contain sequences identical or close to the 59-GCCNNNGGC-39
consensus AP-2 binding sequences. The finding that the prox-
imal 59-GCCNNNGGC-39 sequence but not the distal 59-
CCCCACCC-39 sequences is the functional site that mediates
the trans-activation activity of AP-2 in vivo is interesting in the
context of AP-2 binding sites. It also suggests that being able to
bind to a DNA sequence in vitro does not necessarily impart
functional involvement in vivo. In the human immunodefi-
ciency virus type I gene, AP-2 and NF-kB have been shown to
be able to bind to the same region in a mutually exclusive
manner (29). It should be noted that the sequence 59-
CCCCACCC-39 contains sequences identical to the retinoblas-
toma control element, 59-CCACCC-39. The retinoblastoma con-
trol element motif has been identified as being important for
retinoblastoma-induced trans-activation (30).
AP-2 has been implicated to play a crucial role in the control
of gene expression in response to cell differentiation signals
within neural crest and epidermal cell lineages (28). In the
human tetracarcinoma cell line PA-1, constitutive suppression
of AP-2 transactivator function by stably expressing AP-2B
resulted in a RA-resistant phenotype and these cells became
tumorigenic, suggesting that normal function of AP-2 is re-
quired for these cells to respond to this differentiation signal
(20). Similarly, the neuronal differentiation of human SH-
SY5Y neuroblastoma cells, induced by activation of the protein
kinase C signal pathway, is accompanied by increased AP-2
trans-activator activity (31). Intriguingly, this protein kinase
C-induced SH-SY5Y neuronal differentiation is dependent on
IGF-I. Pahlman et al. (32) reported that while IGF-I is mito-
genic for proliferative SH-SY5Y cells, it loses its mitogenic
response and strongly enhances the neuronal differentiation
when added with phorbol 12-myristate 13-acetate. This
“switch” from a mitogenic effect to a differentiation role for
IGF-I is puzzling since both mitogenic and differentiation ef-
fects are mediated through the IGF-I receptor and this receptor
is expressed and functional in both proliferative and differen-
tiated SH-SY5Y cells. We speculate that this switch may be
related to the potential changes in IGFBPs, since our finding
that AP-2 regulates IGFBP-5 expression raises the possibility
that the production of IGFBP-5 may be activated during the
protein kinase A-induced differentiation in SH-SY5Y cells.
Neuroblastoma cells have been shown to synthesize a number
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of IGFBPs (33, 34), and an increase in IGFBP-5 production is
observed during differentiation of myoblasts (7).
The mechanism underlying the biphasic effect of trans-acti-
vation of human IGFBP-5 gene transcription by AP-2 remains
to be understood, but it is probably related to the transcrip-
tional self-interference of AP-2 reported previously. Kannan et
al. (22) found that overexpression of AP-2 causes inhibition of
AP-2 trans-activation activity mediated by its activation do-
main using an artificial promoter construct. Our data with a
functional promoter are similar in that overexpression of AP-2
results in reduced AP-2 trans-activation activity. It has been
speculated that the AP-2 activity results from a complex of
proteins and that there are cofactors necessary for the AP-2
trans-activation activity, some of which are present in limiting
amounts. Excess AP-2 molecules may interact with one or more
of these putative cofactor(s), making them unavailable for the
AP-2 molecules that are bound to the target site and therefore
causing autointerference (22). Such autointerference has been
reported with GAL4-VP16 (35). In support of the concept of
transcriptional self-interference of AP-2, our studies with cell
lines expressing different levels of endogenous AP-2 showed
that greater amounts of AP-2 plasmid are required for the
autoinhibitory effect in AP-2-deficient cells such as HepG2
cells.
In summary, we have demonstrated that AP-2 regulates
transcription of the human IGFBP-5 gene. We have identified
the proximal 59-GCCNNNGGC-39-like sequences in the human
IGFBP-5 gene where AP-2 is able to bind and trans-activate the
gene. It should be noted that the structure of the IGFBP-5
promoter is highly conserved, since proximal 200 bp of human
mouse and rat IGFBP-5 gene promoters are more than 90%
identical (9, 17, 23). In particular, the proximal AP-2 binding
sequence found in human gene is identical to the analogous
part of the rat and mouse genes. In addition, cAMP induces
IGFBP-5 mRNA in other mammalian species (16). Therefore,
the regulation of IGFBP-5 gene expression by the transcrip-
tional factor AP-2 is likely to be a general mechanism for
mammals. The identification of the role of AP-2 and of a func-
tional binding motif in the IGFBP-5 gene has provided neces-
sary information to warrant future interest. Normal AP-2 func-
tion is involved in the control of a number of cellular events
including cell growth and differentiation (36). The involvement
in these events is an interesting characteristic AP-2 has in
common with the IGF system. Further studies will focus on
these specific cellular events and how they work together to
control IGFBP-5 levels and cell growth and differentiation.
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